Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistMane & Steel sold unapproved and misbranded compounded semaglutide drugs over the internet, making false claims such as "Clinically Proven Weight Loss" and marketing the products as equivalent to FDA-approved therapies. The company violated the Federal Food, Drug, and Cosmetic Act by using misleading advertising and labeling that misrepresented compounded drugs—which are not FDA-approved—as having the same clinical efficacy as approved products. These marketing violations constitute misbranding under sections 502(a) and 502(bb) of the FDCA and the unlawful introduction of drugs into interstate commerce under section 301(a).